Loading clinical trials...
Loading clinical trials...
The primary objective is to show whether rimonabant reduces the risk of a heart attack (MI), stroke, or death from an MI or stroke in patients with abdominal obesity with other cardiovascular (CV) ris...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Sanofi
NCT07547098 · Cardiovascular Diseases (CVD), Chronic Kidney Disease, and more
NCT06675552 · Heart Disease, Heart Failure, and more
NCT07491315 · Fatigue Syndrome, Chronic, Cardiovascular Diseases
NCT07487363 · Atherosclerotic Cardiovascular Diseases, Endothelial Dysfunction
NCT07256249 · Cardiovascular Diseases
Sanofi-Aventis Administrative Office
Bridgewater, New Jersey
Sanofi-Aventis Administrative Office
Buenos Aires
sanofi-aventis Australia & New Zealand administrative office
Macquarie Park, New South Wales
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions